# SOSTDC1

## Overview
SOSTDC1, or sclerostin domain containing 1, is a gene that encodes a secreted protein involved in the regulation of key signaling pathways, particularly the Wnt and bone morphogenetic protein (BMP) pathways. The protein, also referred to as sclerostin domain-containing protein-1, is characterized by a cystine knot-like domain, which is a structural motif common in growth factors, and plays a critical role in modulating cellular processes such as proliferation, differentiation, and apoptosis (Lintern2009Characterization; Tong2022Role). SOSTDC1 is expressed in various tissues, including the skin, intestines, brain, lungs, kidneys, and vasculature, and is notably significant in bone metabolism and tooth development (Tong2022Role). The protein's ability to interact with co-receptors and ligands allows it to act as an antagonist in these pathways, influencing both physiological and pathological processes, such as cancer progression and immune response modulation (Millan2019Sostdc1; Bartolomé2020SOSTDC1).

## Structure
SOSTDC1, also known as sclerostin domain-containing protein-1, is a secreted protein with a molecular weight of 28-32 kDa. It is characterized by a cystine knot-like domain, which is a common structural motif in growth factors, and includes two N-linked glycosylation sites (Lintern2009Characterization; Tong2022Role). The protein is encoded by a 206-amino acid sequence that features a C-terminal cystine knot-like motif and a predicted N-terminal secretion signal (Tong2022Role). 

The cystine knot motif in SOSTDC1 is formed by disulfide bonds, creating a globular protein structure with three loops, typical of BMP antagonists (Lintern2009Characterization). This structural feature is crucial for its function in modulating Wnt and BMP signaling pathways. The protein's interaction with co-receptors such as LRP6 and BMP ligands is facilitated by distinct domains within its structure, allowing it to balance these signaling pathways (Lintern2009Characterization).

SOSTDC1 also has a glycosylated N-terminus, which plays a role in its secretion and interaction with other proteins, such as ALCAM in the context of cancer metastasis (Bartolomé2020SOSTDC1). The protein's structure and post-translational modifications are essential for its diverse biological functions.

## Function
SOSTDC1, also known as sclerostin domain-containing protein-1, is a secreted protein that plays a crucial role in modulating the Wnt and bone morphogenetic protein (BMP) signaling pathways. It acts as an antagonist to these pathways, which are essential for various biological processes, including cellular proliferation, differentiation, and programmed cell death (Lintern2009Characterization; Tong2022Role). SOSTDC1 is expressed in multiple tissues, such as the skin, intestines, brain, lungs, kidneys, and vasculature, and is particularly significant in bone metabolism and tooth development (Tong2022Role).

In the skeletal system, SOSTDC1 negatively regulates bone formation by inhibiting osteoblast differentiation, thereby maintaining bone homeostasis by balancing bone formation and resorption (Tong2022Role). It achieves this by blocking the activities of Wnt ligands and binding to BMPs, affecting the phosphorylation of R-Smads, which are critical for osteoblast differentiation (Tong2022Role). SOSTDC1's regulation of these pathways is also crucial for proper tooth morphogenesis, controlling tooth number, size, and morphology (Tong2022Role). Additionally, SOSTDC1 influences immune responses by modulating NK cell maturation and cytotoxicity through its expression in T cells, affecting the Wnt signaling pathway (Millan2019Sostdc1).

## Clinical Significance
Mutations and alterations in the expression of the SOSTDC1 gene have significant clinical implications in various cancers. In colorectal cancer, SOSTDC1 is overexpressed in metastatic cells and promotes invasion and liver metastasis through its interaction with ALCAM/CD166. This interaction activates signaling pathways such as Src and PI3K/AKT, which are crucial for cancer progression. Silencing SOSTDC1 reduces liver metastasis, suggesting its potential as a therapeutic target (Bartolomé2020SOSTDC1).

In non-small cell lung cancer (NSCLC), SOSTDC1 is significantly down-regulated, and its low expression correlates with poor prognosis. Ectopic expression of SOSTDC1 inhibits cell proliferation by increasing levels of cell cycle inhibitors, indicating its role as a tumor suppressor (Liu2016SOSTDC1).

In Wilms tumors, SOSTDC1 mutations, such as L50F and Q129L, are associated with reduced expression levels, suggesting a tumor suppressive role. These mutations may impact the gene's ability to regulate the Wnt signaling pathway, which is crucial for tumor suppression (Ohshima2009Two).

SOSTDC1's role in cancer is multifaceted, acting as both a tumor suppressor and promoter depending on the cancer type and context (Tong2022Role).

## Interactions
SOSTDC1, also known as sclerostin domain containing 1, is involved in various protein interactions that influence its role in biological processes. It interacts with ALCAM (Activated Leukocyte Cell Adhesion Molecule), a cell adhesion molecule linked to cancer progression. This interaction is crucial for promoting invasion and metastasis in colorectal cancer, as it activates signaling pathways such as Src and PI3K/AKT (Bartolomé2020SOSTDC1). The interaction between SOSTDC1 and ALCAM is mediated by the N-terminal region of SOSTDC1, which contains motifs similar to CD6 binding sequences (Bartolomé2020SOSTDC1).

SOSTDC1 also interacts with bone morphogenetic proteins (BMPs), acting as an inhibitor. It binds to BMPs through its cystine knot structural motif, inhibiting BMP-induced phosphorylation of R-Smads-1, -5, and -8 (Tong2022Role). This interaction is significant in regulating bone metabolism and development, as well as in cancer biology, where SOSTDC1 modulates BMP signaling pathways to influence cancer progression (Tong2022Role).

In the context of tooth development, SOSTDC1 is part of a feedback loop involving Wnt and Shh signaling pathways, where it acts as an inhibitor of Wnt signaling by interacting with LRP4, LRP5, and LRP6 co-receptors (Tong2022Role; Cho2011Interactions).


## References


[1. (Millan2019Sostdc1) Alberto J. Millan, Sonny R. Elizaldi, Eric M. Lee, Jeffrey O. Aceves, Deepa Murugesh, Gabriela G. Loots, and Jennifer O. Manilay. Sostdc1 regulates nk cell maturation and cytotoxicity. The Journal of Immunology, 202(8):2296–2306, April 2019. URL: http://dx.doi.org/10.4049/jimmunol.1801157, doi:10.4049/jimmunol.1801157. This article has 10 citations.](https://doi.org/10.4049/jimmunol.1801157)

[2. (Lintern2009Characterization) Katherine B. Lintern, Sonia Guidato, Alison Rowe, José W. Saldanha, and Nobue Itasaki. Characterization of wise protein and its molecular mechanism to interact with both wnt and bmp signals. Journal of Biological Chemistry, 284(34):23159–23168, August 2009. URL: http://dx.doi.org/10.1074/jbc.M109.025478, doi:10.1074/jbc.m109.025478. This article has 144 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M109.025478)

[3. (Liu2016SOSTDC1) Lei Liu, Shanshan Wu, Yi Yang, Junchao Cai, Xun Zhu, Jueheng Wu, Mengfeng Li, and Hongyu Guan. Sostdc1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation. Cell &amp; Bioscience, April 2016. URL: http://dx.doi.org/10.1186/s13578-016-0091-9, doi:10.1186/s13578-016-0091-9. This article has 20 citations.](https://doi.org/10.1186/s13578-016-0091-9)

[4. (Cho2011Interactions) Sung-Won Cho, Sungwook Kwak, Thomas E. Woolley, Min-Jung Lee, Eun-Jung Kim, Ruth E. Baker, Hee-Jin Kim, Jeon-Soo Shin, Cheryll Tickle, Philip K. Maini, and Han-Sung Jung. Interactions between shh, sostdc1 and wnt signaling and a new feedback loop for spatial patterning of the teeth. Development, 138(9):1807–1816, May 2011. URL: http://dx.doi.org/10.1242/dev.056051, doi:10.1242/dev.056051. This article has 106 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.056051)

[5. (Bartolomé2020SOSTDC1) Rubén A. Bartolomé, Laura Pintado-Berninches, Marta Jaén, Vivian de Los Ríos, Juan Ignacio Imbaud, and J. Ignacio Casal. Sostdc1 promotes invasion and liver metastasis in colorectal cancer via interaction with alcam/cd166. Oncogene, 39(38):6085–6098, August 2020. URL: http://dx.doi.org/10.1038/s41388-020-01419-4, doi:10.1038/s41388-020-01419-4. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-020-01419-4)

[6. (Ohshima2009Two) Junjiro Ohshima, Masayuki Haruta, Yasuhito Arai, Fumio Kasai, Yuiko Fujiwara, Tadashi Ariga, Hajime Okita, Masahiro Fukuzawa, Jun‐Ichi Hata, Hiroshi Horie, and Yasuhiko Kaneko. Two candidate tumor suppressor genes, meox2 and sostdc1, identified in a 7p21 homozygous deletion region in a wilms tumor. Genes, Chromosomes and Cancer, 48(12):1037–1050, September 2009. URL: http://dx.doi.org/10.1002/gcc.20705, doi:10.1002/gcc.20705. This article has 31 citations.](https://doi.org/10.1002/gcc.20705)

[7. (Tong2022Role) Xiaoyang Tong, Chenyu Zhu, Lifei Liu, Mei Huang, Jiake Xu, Xi Chen, and Jun Zou. Role of sostdc1 in skeletal biology and cancer. Frontiers in Physiology, October 2022. URL: http://dx.doi.org/10.3389/fphys.2022.1029646, doi:10.3389/fphys.2022.1029646. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2022.1029646)